Cancer Research Cancer Health Disparities Conference 2009
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Meeting Abstracts Online

[Cancer Research 50, 2818-2822, May 1, 1990]
© 1990 American Association for Cancer Research

This Article
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Chatterjee, M.
Right arrow Articles by Harris, A. L.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Chatterjee, M.
Right arrow Articles by Harris, A. L.

Reversal of Multidrug Resistance by Verapamil and Modulation by {alpha}1-Acid Glycoprotein in Wild-type and Multidrug-resistant Chinese Hamster Ovary Cell Lines

Mitali Chatterjee, Craig N. Robson and Adrian L. Harris1

Cancer Research Unit, University of Newcastle Upon Tyne, Medical School, Framlington Place, Newcastle Upon Tyne, United Kingdom NE2 4HH [M. C.], and Imperial Cancer Research Fund, Institute of Molecular Medicine, John Radcliffe Hospital, Headington, Oxford, United Kingdom OX3 9DU [C. N. R., A. L. H.]

Multidrug resistance can be reversed by a range of "calcium channel"-blocking drugs in vitro, of which verapamil is the most widely used. Verapamil is bound to {alpha}1-acid glycoprotein (AAG) in vivo in humans but is absent from calf serum, used in tissue culture media. The effect of AAG on the ability of verapamil to alter Adriamycin cytotoxicity was assessed in parental Chinese hamster ovary cells (CHO-K1) and in a multidrug-resistant subline (CHO-Adrr). In both the parental and the resistant cells, there was a dose-related potentiation of Adriamycin cytotoxicity by verapamil. At 10 µM verapamil, there was a 5-fold decrease in the concentration of Adriamycin that caused 50% reduction in growth of CHO-K1 cells but a 15-fold decrease in CHO-Adrr cells. In the presence of increasing AAG concentrations within the range found in cancer patients, there was a concentration-related reduction in the effects of verapamil. In CHO-Adrr cells, there was complete reversal of the potentiating effect of 10 µM verapamil at 2 mg/ml AAG. In contrast, in CHO-K1 cells, AAG reduced the effects of verapamil by only 20% at a similar concentration. There was a much higher internal uptake of fluorescein-labeled AAG by CHO-Adrr cells than by CHO-K1 cells. These results suggest that, in addition to a plasma membrane site, there may be a major endosomal site of action of verapamil in multidrug-resistant cells. The implications are that verapamil in vivo in the presence of AAG may effectively reverse low levels of multidrug resistance, but not high levels. Thus selection of patients with low AAG levels may be appropriate for clinical studies.

1 To whom requests for reprints should be addressed.

Received 7/28/89. Revised 1/ 9/90.





HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Meeting Abstracts Online
Copyright © 1990 by the American Association for Cancer Research.